Plasma exosomal miR-483-3p induces myocardial injury by suppressing autophagy via targeting XPO1 in OSA
Quick Facts
- Publication title: Plasma exosomal miR-483-3p induces myocardial injury by suppressing autophagy via targeting XPO1 in OSA
- Journal: Life Sci
- Year: 2025
- DOI: 10.1016/j.lfs.2025.123809
- PMID/PMCID: 40505833
Research overview
This study provides new mechanistic insights into the molecular pathways underlying OSA-induced cardiac damage and identifies miR-483-3p as a potential biomarker and therapeutic target. Plasma exosomes, known to regulate cellular processes by transporting microRNAs (miRNAs), have been implicated in OSA-induced endothelial dysfunction.
Key findings
Plasma exosomes from OSA patients were found to deliver miR-483-3p into myocardial cells, where it downregulated XPO1, inhibited autophagy, and induced myocardial hypertrophy.
This process elevated myocardial injury markers, and impaired cardiac function.
Levels of plasma exosomal miR-483-3p were positively correlation with myocardial injury markers in OSA patients.
Study design
Plasma exosomes were isolated from plasma of non-OSA controls (CON-Exos) and OSA patients (OSA-Exos) using differential centrifugation.
The exosomes were co-cultured with myocardial cells or administered to mice via the tail vein injections.
High-throughput sequencing and RT-PCR screened for enriched miRNAs in OSA-Exos, with bioinformatics predicting target genes.
Echo Biotech Role
Echo Biotech contributed miRNA profiling/sequencing and bioinformatic analysis, qPCR validation.
Related platforms: Exoomics®
Related services and capabilities: EV miRNA Profiling / Sequencing, qPCR Validation
References
Original publication: Plasma exosomal miR-483-3p induces myocardial injury by suppressing autophagy via targeting XPO1 in OSA Life sciences. 2025. DOI: 10.1016/j.lfs.2025.123809. PMID/PMCID: 40505833.